[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640735":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":28,"collaborators":11,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":34,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":11,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":54,"overallStatus":57,"whyStopped":11,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":65,"locationsCount":11},{"fullName":5,"class":6},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Two-stage","EXPERIMENTAL",null,[13],"Other: Two-stage calcium supplementation in RCA-CRRT",{"label":15,"type":16,"description":11,"interventionNames":17},"Control","ACTIVE_COMPARATOR",[18],"Other: Commercial RCA-CRRT module",[20,24],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"Two-stage calcium supplementation in RCA-CRRT","The two-stage calcium supplementation refers to: the first stage after the initiation of CRRT, the amount of calcium supplementation includes the calcium clearance from the extracorporeal circuit and the accumulated calcium citrate in the body; when the blood citrate concentration reaches a steady state, the second stage begins, at which point the accumulated calcium is stable and only the calcium clearance from the extracorporeal circuit needs to be supplemented.",[9],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"Commercial RCA-CRRT module","The recommended supplementation method for citrate and calcium agents in the CRRT citrate module by Fresenius Medical Care.",[15],{"type":29,"investigatorFullName":30,"investigatorTitle":31,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Ding Feng","Professor","100640735","personalized-two-stage-regional-citrate-anticoagulation-for-crrt-in-patients-with-citrate-metabolism-impairment-100640735",false,"NCT07579663","Personalized Two-stage Regional Citrate Anticoagulation for CRRT in Patients With Citrate Metabolism Impairment","Personalized Two-stage Regional Citrate Anticoagulation for CRRT in Patients With Citrate Metabolism Impairment: a Multicenter Randomized Controlled Study","PRECISE","Inclusion Criteria:\n\nA. Aged 18 to 80 years, inclusive, male or female; B. Diagnosed with acute kidney injury or chronic kidney disease stage 5, and assessed by a physician as requiring continuous renal replacement therapy (CRRT); C. Citrate metabolism disorder, including liver failure (acute liver failure, acute-on-chronic liver failure, or decompensated cirrhosis), and\u002For microcirculation disorder (mean arterial pressure \\\u003C65 mmHg requiring vasopressor therapy and lactate ≥2 mmol\u002FL); D. The investigator determines that the patient can have a stable vascular access established (the access must be capable of providing a constant and effective blood flow rate \\>150 ml\u002Fmin); E. The study participant (subject) and their legal guardian are able to understand the study purpose and provide written informed consent.\n\nExclusion Criteria:\n\nA. Received regional citrate anticoagulation therapy within the previous 72 hours; B. Expected to require additional non-protocol calcium supplementation during CRRT due to disease-related needs; C. Requiring arterial-venous reversal of the extracorporeal circuit during CRRT due to poor flow; D. Requiring concurrent peritoneal dialysis during the trial period; E. Participated in or is currently participating in another clinical trial within 1 month prior to the date of signing the informed consent form; F. Expected survival time less than 72 hours; G. Any other conditions that, in the investigator's judgment, make the patient unsuitable for participation in the clinical trial.","ALL","18 Years","80 Years",{"count":44,"type":45},142,"ESTIMATED","INTERVENTIONAL",[48],"NA","The purpose of this study is to compare the efficacy and safety of an individualized two-stage calcium supplementation method versus a conventional commercial RCA-CRRT module in RCA-CRRT for patients with citrate metabolism disorders.",[51,52,53],"AKI - Acute Kidney Injury","CKD 5D, Hemodialysis","Hepatic Failure",[55,56],"Regional Citrate Anticoagulation (RCA)","Continuous Renal Replacement Therapy (CRRT)","NOT_YET_RECRUITING","2026-05-05",{"date":60,"type":61},"2026-05-12","ACTUAL",{"date":58,"type":45},{"date":64,"type":45},"2028-08-14",{"name":5,"class":6}]